1-8 of 8
Harry H. Yoon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study

Andrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, Rama Suresh, Albert C. Lockhart, Amberly Brown, Marcus Breden, Jad I. Belle, John Herndon, Savannah J. Bogner, Katrina Pedersen, Benjamin Tan, Nicholas Boice, Abhi Acharya, Mina Abdiannia, Feng Gao, Harry H. Yoon, Mojun Zhu, Nikolaos A. Trikalinos, Lee Ratner, Olivia Aranha, William G. Hawkins, Brett H. Herzog, David G. DeNardo
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4698.
https://doi.org/10.1158/1078-0432.CCR-23-2993
Published: 14 November 2023
View article titled, Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study
Open the PDF for Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study in another window
Journal Articles

Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

Andrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, Rama Suresh, Albert C. Lockhart, Amberly Brown, Marcus Breden, Jad I. Belle, John Herndon, Savannah J. Bogner, Katrina Pedersen, Benjamin Tan, Nicholas Boice, Abhi Acharya, Mina Abdiannia, Feng Gao, Harry H. Yoon, Mojun Zhu, Nikolaos A. Trikalinos, Lee Ratner, Olivia Aranha, William G. Hawkins, Brett H. Herzog, David G. DeNardo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (24): 5254–5262.
https://doi.org/10.1158/1078-0432.CCR-22-0308
Published: 15 December 2022
View article titled, Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
Open the PDF for Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study in another window
Includes: Supplementary data
Journal Articles

Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise

Harry H. Yoon, Haidong Dong, Qian Shi
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3173–3175.
https://doi.org/10.1158/1078-0432.CCR-22-0932
Published: 02 August 2022
View article titled, Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise
Open the PDF for Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise in another window
Journal Articles

Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction

Mojun Zhu, Chunhua Chen, Nathan R. Foster, Christopher Hartley, Taofic Mounajjed, Marcela A. Salomao, Briant F. Fruth, Staci E. Beamer, Yohan Kim, Susan M. Harrington, Henry C. Pitot, Cristobal T. Sanhueza, Yening Feng, Joerg Herrmann, Robert R. McWilliams, Fabrice Lucien, Bing Q. Huang, Wen Wee Ma, Tanios S. Bekaii-Saab, Haidong Dong, Dennis Wigle, Daniel H. Ahn, Chris L. Hallemeier, Shanda Blackmon, Harry H. Yoon
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (14): 3021–3031.
https://doi.org/10.1158/1078-0432.CCR-22-0413
Published: 15 July 2022
View article titled, Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction
Open the PDF for Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction in another window
Includes: Supplementary data
Journal Articles

Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis

Harry H. Yoon, Qian Shi, Erica N. Heying, Andrea Muranyi, Joerg Bredno, Faith Ough, Azita Djalilvand, June Clements, Rebecca Bowermaster, Wen-Wei Liu, Michael Barnes, Steven R. Alberts, Kandavel Shanmugam, Frank A. Sinicrope
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 125–133.
https://doi.org/10.1158/1078-0432.CCR-18-1984
Published: 03 January 2019
View article titled, Intertumoral Heterogeneity of CD3<sup>+</sup> and CD8<sup>+</sup> T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis
Open the PDF for Intertumoral Heterogeneity of CD3<sup>+</sup> and CD8<sup>+</sup> T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis in another window
Includes: Supplementary data
Journal Articles

Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)

Frank A. Sinicrope, Michelle R. Mahoney, Harry H. Yoon, Thomas C. Smyrk, Stephen N. Thibodeau, Richard M. Goldberg, Garth D. Nelson, Daniel J. Sargent, Steven R. Alberts
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (23): 5294–5304.
https://doi.org/10.1158/1078-0432.CCR-15-0527
Published: 30 November 2015
View article titled, Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)
Open the PDF for Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance) in another window
Includes: Supplementary data
Journal Articles

KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)

Harry H. Yoon, David Tougeron, Qian Shi, Steven R. Alberts, Michelle R. Mahoney, Garth D. Nelson, Suresh G. Nair, Stephen N. Thibodeau, Richard M. Goldberg, Daniel J. Sargent, Frank A. Sinicrope, for the Alliance for Clinical Trials in Oncology
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (11): 3033–3043.
https://doi.org/10.1158/1078-0432.CCR-13-3140
Published: 29 May 2014
View article titled, <em>KRAS</em> Codon 12 and 13 Mutations in Relation to Disease-Free Survival in <em>BRAF</em>–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)
Open the PDF for <em>KRAS</em> Codon 12 and 13 Mutations in Relation to Disease-Free Survival in <em>BRAF</em>–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance) in another window
Includes: Supplementary data
Journal Articles

Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas

Harry H. Yoon, Qian Shi, William R. Sukov, Anne E. Wiktor, Maliha Khan, Christopher A. Sattler, Axel Grothey, Tsung-Teh Wu, Robert B. Diasio, Robert B. Jenkins, Frank A. Sinicrope
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (2): 546–554.
https://doi.org/10.1158/1078-0432.CCR-11-2272
Published: 16 January 2012
View article titled, Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas
Open the PDF for Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas in another window
Includes: Supplementary data